Story perspectives

Retatrutide Cuts Sleep Apnea Breathing Interruptions in Phase 3

By Drooid · Oct 28, 2026 · How we work

Read the story

Story summary

Summary

Eli Lilly reported that retatrutide markedly reduced breathing interruptions in obese adults with sleep apnea.
In phase 3 trials, 68% of 691 participants achieved over 50% improvement in OSA symptoms.
Hypoxic burden fell about 75% in non-diabetics and 65% in type 2 diabetics.
Retatrutide also induced 12%-20% weight loss and reduced blood pressure, LDL cholesterol, and inflammation.
Eli Lilly plans to file an FDA application for retatrutide in early 2027.

Summary

U.S. District Judge Zahid Quraishi denied Novo Nordisk’s request for a preliminary injunction against Eli Lilly’s ads.
Quraishi said Novo Nordisk failed to show irreparable harm or loss of goodwill.
The ruling noted Eli Lilly’s advertisements produced only negligible market impact from April to July.
Judge suggested monetary damages could compensate Novo Nordisk for any nontrivial harm absent an injunction.

1 of 2

Eli Lilly Retatrutide Trial

Eli Lilly reported that retatrutide markedly reduced breathing interruptions in obese adults with sleep apnea.
In phase 3 trials, 68% of 691 participants achieved over 50% improvement in OSA symptoms.
Hypoxic burden fell about 75% in non-diabetics and 65% in type 2 diabetics.
Retatrutide also induced 12%-20% weight loss and reduced blood pressure, LDL cholesterol, and inflammation.
Eli Lilly plans to file an FDA application for retatrutide in early 2027.

1 / 2